Jackie Z United States

Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas. 

Company Size (Fulltime employees)
Year of foundation
1991
Please specify your partnering goal
Win-win
Headquartner in China
Biotech/Pharma Category
Slides Deck
(pdf, 617.13KB)
Myriad Genetics
Business Development Lead 
Functionality

Kristina Zakurdaeva United States

Incuron is a private clinical-stage company that develops a novel class of synthetic small molecules, Curaxins, with a unique multi-targeted mechanism of antitumor activity. These chromatin damaging agents interfere with histone/DNA binding causing decondensation of chromatin in tumor cells, functional inactivation of histone chaperone FACT, and simultaneous effect on a set of universal previously undruggable targets, leading to inhibition of pro-cancer transcriptional factors, MYC, NF-kB, HIF1a, and HSF-1, and activation of the tumor suppressor p53, as well as induction of type I interferon response.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.

Website:
incuron.com
Headquartner in China
Assets Information 1
The clinical lead curaxin CBL0137 demonstrated dose-dependent, nonclinical efficacy in several preclinical adult and pediatric solid and hematological tumor models, and synergistic activity with multiple conventional drugs. Two Phase 1 clinical trials of CBL0137 in advanced solid tumors (oral and IV formulations) were completed with the results presented at the 2020 ASCO Virtual Annual Meeting (Poster 313 (abstract 3583) and Poster 337 (abstract 3607)). CBL0137 demonstrated favorable pharmacology, a manageable safety profile, and preliminary evidence of antitumor activity with protracted stable disease. It was also studied in patients with hematologic malignancies. Additionally, a Phase I clinical trial of intra-arterial administration to patients with sarcoma or melanoma of extremities is ongoing (NCT03727789). A clinical program in pediatric oncology iscurrently under development. CBL0137 crosses the blood-brain barrier, supporting potential utility in CNS tumors.
Biotech/Pharma Asset Stage
Incuron, Inc.
CEO 
Functionality

Stephen Zeng China

IHM-GBA is short for Innovation center of High-performance Medical device in Greater Bay Area. It's based in Guangzhou of Guangdong province in China. We focus on investment, partnership, and collaboration in global disruptive technology in medical device. We aim at helping global startups to enter into and develop the Chinese market. We are in comprehensive discussion with companies in terms of investment, partnership, licensing, and others.
Website:
www.ihm-gba.com
Year of foundation
2019
Headquartner in China
IHM-GBA
Director 
Functionality

Willys Zhai United Kingdom

医疗专业精品投行
Partnering Objectives
Headquartner in China
Medbio Capital
MD 

Jimmy Zhang

AccuGen Group Yeehong Business School
CEO Adjunt Professor, Master Student Mentor 

Xu Zhang China

Partnering Objectives
Tianjin Medical University
Professor 

Wei Zhang China

Illumina is a provider of Next Generation Sequencing technology
Website:
www.illumina.com
Partnering Objectives
Headquartner in China
illumina
senior clinical specialist 

Mingzhu Zhang China

CRO based in Shanghai
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Working with clients with preclinical R&D needs
Headquartner in China
Shanghai Medicilon
VP of Business Development  

Jeffrey Zhang

Stemirna Therapeutics
CEO&CBO, Stemirna Therapeutics President, CHBD 

Yanping Zhang China

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.
Website:
www.btyy.com
Partnering Objectives
Headquartner in China
Chengdu Brilliant Pharmaceutical Co., Ltd.
BD